证券日报网1月21日讯，正海生物（300653）在接受调研者提问时表示，首先从口腔种植市场看，随着 种植手术服务限价、种植体集采等一系列举措降低了人们接受种植牙手术的医疗成本，激发了牙种植市 场需求，同时对比欧美及韩国等发达国家，我国在种植牙渗透率上较上述国家及地区仍有很大差距，种 植牙渗透率提升仍有巨大空间，公司对口腔种植行业市场的发展潜力和增长空间长期看好，公司也会持 续深耕这一优势领域，在巩固现有市场份额的同时，积极结合新品推广，力求打开更多市场空间。公司 脑膜产品市场方面，得益于脑膜集采政策的全面铺开及行业的产品高国产化率，行业发展总体趋于成熟 稳健。公司脑膜系列产品通过积极参与集采项目并持续中标，稳固并提升了市场份额，基于行业稳定度 及产品的市场地位，脑膜系列产品会成为长期稳定公司营收收入基本盘的主力产品。 ...

证券日报网1月21日讯 ，正海生物在接受调研者提问时表示，宫腔修复膜产品于今年1月上旬正式推入 注册阶段，目前已取得注册受理通知书，后续还有审评审批、制证等环节。乳房补片项目于2025年11月 完成了临床试验总结工作，目前正在进行产品注册准备工作。产品后续开发进展，公司也将按照监管要 求履行信息披露义务。 （编辑 袁冠琳） ...

证券日报网1月21日讯 ，正海生物在接受调研者提问时表示，公司钙硅生物陶瓷口腔骨修复材料的适用 范围是：产品需要与屏障膜联合使用，适用于牙槽骨缺损修复。公司在产品取证前便在产品转产、品牌 宣传搭建等方面提前部署了准备工作，产品产能储备充足，为产品快速上市销售提供了必要条件。产品 推广策略的制定会充分结合产品在原料组分、工艺结构等方面的创新优势以及目标市场的综合情况，通 过差异化营销策略推进产品上市推广，以实现产品盈利水平最大化。 （编辑 袁冠琳） ...

（编辑 袁冠琳） 证券日报网1月21日讯 ，正海生物在接受调研者提问时表示，口腔修复膜营收有所降低，主要受产品价 格波动影响，近几年口腔民营市场受到竞争加剧、终端降本控费等因素影响，口腔种植需求增长趋势放 缓。公司为应对市场竞争，坚定执行精准化营销策略，发挥产品在规模及成本方面的优势，全面梳理优 化产品价格，增进与头部终端的紧密合作，稳定渠道对市场份额的覆盖，巩固了产品的头部地位。口腔 板块作为公司发展的重要方向，未来仍将持续深耕该领域，推进口腔新品的加速上市销售，协同发挥膜 粉产品组合能力，进一步提升公司的核心竞争力。 ...

（文章来源：证券日报） 证券日报网1月21日讯 ，正海生物在接受调研者提问时表示，公司会结合未来发展战略需要以及公司资 本结构状况总体考量公司融资的必要性及后续具体的融资计划。 ...

每经头条（nbdtoutiao）——重磅数据公布：回升！专访徐洪才："内卷式竞争"得到一定缓解，下一 步"补收入"可形成良性循环 每经AI快讯，正海生物发布公告称，2026年1月20日，正海生物接受华西证券调研，公司董事会秘书、 副总经理兼财务总监赵丽女士参与接待，并回答了投资者提出的问题。 （记者 张喜威） ...

Core Insights - The Chinese nanosphere industry is experiencing rapid growth, with a projected market size of approximately 4.236 billion yuan in 2024, representing a year-on-year increase of 5.40% [2][11] - Nanospheres are critical materials in high-tech products, serving as essential components in biomedicine and flat panel displays, thus being referred to as "behind-the-scenes heroes" and "bottleneck" materials [2][11] Industry Overview - Nanospheres are micron-sized spheres with nanometer-scale pore structures, characterized by high specific surface area and unique physicochemical properties, widely used in drug delivery, LCD displays, bioseparation, medical diagnostics, and optoelectronic materials [2] - They can be classified into natural biomaterials (e.g., chitosan, collagen) and synthetic polymers (e.g., PLGA, PVA) [4] Preparation Methods - Nanospheres can be prepared using various methods, including ionic crosslinking, emulsification-solvent evaporation, and microfluidic technology, each with distinct principles, applicable materials, and performance characteristics [5][7] - Ionic crosslinking is suitable for natural biomaterials and emphasizes biocompatibility, while emulsification-solvent evaporation is widely used for synthetic polymers, and microfluidic technology allows for precise control of droplet formation [7] Industry Chain - The upstream of the nanosphere industry includes raw materials such as chitosan, starch, cellulose, and various synthetic polymers, along with production equipment like high-pressure homogenizers and laser particle size analyzers [8][9] - The midstream involves the manufacturing of nanospheres, while the downstream applications include drug delivery, biopurification, in vitro diagnostics, LCD spacers, and conductive materials [8] Market Size - The market for nanospheres in China is projected to grow significantly, with the biomedicine sector utilizing uniform-sized, surface-modifiable nanospheres for high-end drug development and precise diagnostics [11]

Group 1: Revenue and Market Trends - The company's oral repair membrane revenue has slightly declined in the past two years due to product price fluctuations and increased competition in the private dental market [4] - The demand for dental implants is slowing down, but the company aims to strengthen its market position through precise marketing strategies and collaboration with leading end-users [4] - The company remains optimistic about the growth potential in the dental implant market, as there is still a significant gap in penetration rates compared to developed countries [5] Group 2: Product Development and Market Position - The company’s calcium silicate bio-ceramic oral bone repair material is designed for use with barrier membranes and is suitable for alveolar bone defect repair [4] - The company has prepared for product launch by ensuring sufficient production capacity and developing a differentiated marketing strategy based on innovative material components [4] - The uterine repair membrane is currently in the registration phase, while the breast patch project has completed clinical trials and is preparing for registration [6] Group 3: Future Plans and Financing - The company will assess the necessity of financing based on future strategic needs and overall capital structure [6] - The company is committed to maintaining transparent communication with investors and adhering to information disclosure regulations [6]

Financial Performance - In the first three quarters of 2025, the company's net profit experienced a year-on-year decline due to multiple factors, including an increase in VAT from 3% to 13% [3] - Market demand fluctuations for key products, particularly oral products, necessitated price optimization, while the procurement project for meninges products led to a cautious market sentiment [3] - Increased sales expenses for new product promotions and targeted marketing exerted pressure on operating profits in 2025 [3] Future Plans - For 2026, the company aims to deepen its presence in advantageous sectors, particularly with the launch of calcium silicate bioceramic oral bone repair materials, to enhance competitive capabilities in the oral market [3] - The company plans to integrate existing resources to boost the volume of active biological bone products and expand revenue contributions [3] - Efforts will be made to innovate and explore new business opportunities [3] Product Development and Market Strategy - As of now, 6 provincial and 2 inter-provincial alliances have initiated bulk procurement for meninges products, covering a total of 24 provinces [4] - The company is preparing for the bidding process for the Tianjin medical procurement center's bulk procurement project for medical consumables [4] - A comprehensive product promotion strategy is in place for the calcium silicate bioceramic oral bone repair materials, focusing on innovative advantages and market conditions to maximize profitability [4] International Expansion - The company is assessing the potential for international sales of multiple products, evaluating market entry barriers and potential returns in various countries [4] Customer Education and Talent Acquisition - The company engages in academic conferences and professional exhibitions to enhance product recognition among professional clients, including doctors and medical institutions [5] - Collaboration with organizations like the China Dental Disease Prevention Foundation aims to address urgent clinical repair needs for patients [5] - Talent acquisition strategies include leveraging existing platforms for high-end talent recruitment and fostering partnerships with academic institutions for talent development [6]

Group 1 - Defu Technology plans to acquire at least 51% of Huiru Technology through cash purchase and capital increase, aiming for rapid capacity expansion to meet growing downstream demand [2] - Huiru Technology specializes in the R&D, production, and sales of high-performance electrolytic copper foil, with a current production capacity of 20,000 tons per year [2] - East China Pharmaceutical's subsidiary, Daor Biotechnology, has its product DR10624 included in the list of breakthrough therapeutic varieties, targeting severe hypertriglyceridemia [3][18] - DR10624 is a globally first-of-its-kind long-acting tri-specific agonist, showing excellent efficacy in reducing triglycerides and eliminating liver fat in clinical trials [3][18] Group 2 - Xiantan Co. reported a 9.41% year-on-year increase in chicken product sales revenue, reaching 529 million yuan, with sales volume up by 6.76% [4][19] - Jiamei Packaging's stock will resume trading on January 12 after completing a review during its suspension, with a significant price increase of 230.48% during the suspension period [5][20] - Xianle Health plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange, considering the interests of existing shareholders [6][21][22] Group 3 - China Shipbuilding Defense expects a net profit increase of 149.61% to 196.88% for 2025, projecting a profit of 940 million to 1.12 billion yuan [7][23] - Daotong Technology anticipates a net profit growth of 40.42% to 45.10% for 2025, with a projected profit of 900 million to 930 million yuan [8][24] - Huace Navigation forecasts a net profit increase of 14.84% to 18.27% for 2025, estimating a profit of 670 million to 690 million yuan [9][25] Group 4 - Luokai Co. won a procurement project from State Grid Fujian Electric Power, with a total contract value of approximately 48.2 million yuan [10][26] - Minhe Co. reported a 65.22% year-on-year increase in the sales volume of commodity broiler chicks, totaling approximately 29.66 million chicks, with sales revenue up by 53.09% [11][27] - Zhenghai Bio obtained a medical device registration certificate for calcium silicate bio-ceramic oral bone repair materials, suitable for alveolar bone defect repair [12][28] - Three Gorges Energy reported a cumulative total power generation increase of 5.99% for 2025, with a total generation of 762.61 billion kWh [13][29] - Huisheng Bio expects a net profit of 235 million to 271 million yuan for 2025, marking a turnaround from a loss in the previous year [14][30]